|Year : 2017 | Volume
| Issue : 2 | Page : 109-111
The nomadic Ozurdex®: Anterior migration of the dexamethasone implant and back!
Priya Srinivasan, Chaitra Jayadev, Rohit Shetty
Department of Vitreoretina, Narayana Nethralaya Eye Institute, Bengaluru, Karnataka, India
|Date of Web Publication||29-Jun-2017|
121/C, West of Chord Road, Rajajinagar, 1st ‘R’ Block, Bengaluru - 560 010, Karnataka
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Dexamethasone intravitreal implantation has been used in various retinal and uveal pathologies. Common complications include cataract formation and raised intraocular pressure. Although uncommon, migration of the implant has also been well reported. We describe a case with migration of the implant into the anterior chamber in a patient with a scleral-fixated intraocular lens, which was managed noninvasively by pupillary dilatation and positioning of the patient.
Keywords: Anterior migration, cystoid macular edema, dexamethasone implant
|How to cite this article:|
Srinivasan P, Jayadev C, Shetty R. The nomadic Ozurdex®: Anterior migration of the dexamethasone implant and back!. Oman J Ophthalmol 2017;10:109-11
|How to cite this URL:|
Srinivasan P, Jayadev C, Shetty R. The nomadic Ozurdex®: Anterior migration of the dexamethasone implant and back!. Oman J Ophthalmol [serial online] 2017 [cited 2020 Jan 28];10:109-11. Available from: http://www.ojoonline.org/text.asp?2017/10/2/109/209110
| Introduction|| |
The use of dexamethasone intravitreal implantation (Ozurdex ®, Allergan Inc., Irvine, CA, USA) is becoming increasingly popular in the management of chronic retinal and uveal pathologies. Although the advantages of this treatment are a longer duration of action and lower cost, it is not without complications, which include posterior subcapsular cataract formation, increased intraocular pressure (IOP), and glaucoma. Migration of the implant into the anterior chamber is another known complication in aphakic eyes and pseudophakic eyes, with iris claw lenses and scleral-fixated intraocular lenses (SFIOLs).,, Most of these cases have been managed surgically by removal or repositioning of the implant. Although positioning of patients has successfully restored the implant in eyes with an anterior chamber intraocular lens, there have been no such reports in eyes with SFIOLs.,,
| Case Report|| |
A 60-year-old man underwent vitrectomy and an SFIOL implantation for a traumatic subluxated intraocular lens with retinal detachment in the left eye. Subsequently, he developed cystoid macular edema (CME), for which he was treated with multiple intravitreal injections of bevacizumab and triamcinolone acetonide [Figure 1]. Since the response to these drugs was inadequate, he was advised an intravitreal dexamethasone implantation which he underwent after an informed consent.
|Figure 1: Cystoid macular edema on spectral domain-optical coherence tomography prior to dexamethasone implant|
Click here to view
A month after the implantation, he presented with sudden painless blurring of vision in his left eye of 3 days duration. He also complained of a linear floater. His corrected distance visual acuity (CDVA) had decreased from 20/200 prior to the implantation to 20/2000. Slit-lamp examination revealed corneal edema with Descemet's folds. The dexamethasone implant was seen inferiorly in the anterior chamber, mimicking a hypopyon [Figure 2]. Anterior segment spectral domain optical coherence tomography (SD-OCT; Avanti, Optovue, CA, USA) scan clearly demonstrated the Descemet's folds and implant in the anterior chamber [Figure 3]. The patient's pupil was pharmacologically dilated and he was advised supine positioning with slight chin elevation to allow the implant to re-enter the posterior segment. When reviewed the next day, the implant had migrated back to the vitreous cavity [Figure 4] and [Figure 5]. He was advised to avoid the prone position and to come for regular follow-up.
|Figure 2: Corneal edema with dexamethasone implant was seen inferiorly in the anterior chamber, simulating a hypopyon (white arrow)|
Click here to view
|Figure 3: Anterior segment spectral domain-optical coherence tomography scan demonstrating Descemet's folds and the dexamethasone implant in the anterior chamber (white arrows)|
Click here to view
|Figure 4: Mild corneal edema and absence of the implant in the anterior chamber on the first follow-up day|
Click here to view
|Figure 5: Anterior segment spectral domain-optical coherence tomography scan demonstrating the re-migration of the dexamethasone implant int o the posterior segment|
Click here to view
A week later, the CDVA had improved to 20/200 and the corneal edema had decreased. Despite the patient not being on miotics prophylactically, the implant did not migrate again into the anterior chamber. Two months postinjection, the CDVA was 20/120 and there was no recurrence of macular edema on the SD-OCT (Spectralis, Heidelberg, Germany) [Figure 6].
|Figure 6: Resolution of cystoid macular edema on spectral domain-optical coherence tomography at 2-month follow-up|
Click here to view
| Discussion|| |
Ozurdex ® (Allergan Inc., Irvine, CA, USA) is a biodegradable intravitreal implant containing dexamethasone 700 μg. It has been used in the treatment of macular edema secondary to central and branch retinal vein occlusions, diabetic macular edema, and for the treatment of noninfectious posterior uveitis. It has also been shown to be effective in refractory pseudophakic CME.,
Although the absence of the lens capsule and prior vitrectomy are the risk factors for migration of the implant into the anterior chamber, it is also reported in cases with an intact posterior capsule., The major complications of anterior chamber migration are corneal edema and elevation of IOP. Corneal endothelial toxicity is possibly due to mechanical trauma from the rigid implant as well as chemical toxicity. Corneal edema is noted when migration of the implant occurs in the early postoperative period and decreases in incidence when it occurs later due to the decreased rigidity of the implant. Unresolved or chronic corneal edema may be severe enough to warrant keratoplasty, thereby justifying an early surgical removal of the implant if it cannot be restored to the vitreous cavity by posturing the patients appropriately. The surgical management strategies include the use of forceps to remove the implant, yttrium-aluminum-garnet laser to fragment the implant, aspiration of the disintegrated implant, and repositioning of the implant into the posterior segment with a 30-gauge needle. There are also reports of the implant being sutured to the sclera using a 10–0 nonabsorbable polypropylene suture to prevent the risk of anterior migration. A no-touch technique for removal of the implant using viscoelastic has also been described.
Although noninvasive repositioning of the implant by posturing has been reported, we describe it in a patient with SFIOL, which helped avoid surgical intervention and allowed the therapeutic effect of the implant to be maintained for 3 months. To prevent the recurrence of migration, use of miotics and avoiding the prone position may help.
Hence, it is important to be cautious while using a dexamethasone implant in patients with aphakia, pseudophakia including SFIOLs, and posterior capsular compromise or zonular dehiscence. With a regular follow-up, early detection of migration can be managed noninvasively, thereby preventing complications such as corneal decompensation and raised IOP.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: Indications and evidence. Adv Ther 2011;28:351-66.
Kapoor KG, Wagner MG, Wagner AL. The sustained-release dexamethasone implant: Expanding indications in vitreoretinal disease. Semin Ophthalmol 2015;30:475-81.
Gullapalli VK, DiLoreto DA. Migration of intravitreal dexamethasone implant to anterior chamber. Retin Cases Brief Rep 2013;7:111-3.
Cronin KM, Govind K, Kurup SK. Late migration of dexamethasone implant into anterior chamber. Arch Ophthalmol 2012;130:711.
Voykov B, Bartz-Schmidt KU. Dislocation of dexamethasone intravitreous implant. Arch Ophthalmol 2012;130:706.
Laplace O, Rodallec T, Akesbi J, Sandali O. Anterior chamber migration of a dexamethasone implant in a pseudophakic patient with a scleral-fixated posterior chamber intraocular lens. J Fr Ophtalmol 2013;36:e59-61.
Vela JI, Crespí J, Andreu D. Repositioning of dexamethasone intravitreal implant (Ozurdex) migrated into the anterior chamber. Int Ophthalmol 2012;32:583-4.
Khurana RN, Appa SN, McCannel CA, Elman MJ, Wittenberg SE, Parks DJ, et al.
Dexamethasone implant anterior chamber migration: Risk factors, complications, and management strategies. Ophthalmology 2014;121:67-71.
Kishore SA, Schaal S. Management of anterior chamber dislocation of dexamethasone implant. Ocul Immunol Inflamm 2013;21:90-1.
Kocak N, Ozturk T, Karahan E, Kaynak S. Anterior migration of dexamethasone implant in a pseudophakic patient with intact posterior capsule. Indian J Ophthalmol 2014;62:1086-8.
] [Full text]
Mateo C, Alkabes M, Burés-Jelstrup A. Scleral fixation of dexamethasone intravitreal implant (OZURDEX®) in a case of angle-supported lens implantation. Int Ophthalmol 2014;34:661-5.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6]